63. [IF=14.3] Aixue Li et al."Cryoshocked Adipocytes Mediated Dual-Modal Strategy Combining Photodynamic Therapy and Triptolide Palmitate for Pulmonary Metastatic Melanoma Treatment."Advanced Science.2025 Jan;:2414307 62. [IF=4.8] Shiyuan Jiang et al."Triptolide combined with salvianolic acid B alleviates CCL4-induced liver fibrosis by suppressing the Th17/IL-17A axis."INTERNATIONAL IMMUNOPHARMACOLOGY.2025 Mar;150:114300 61. [IF=6.9] Liuchunyang Yu et al."Application of galactosylated albumin for targeted delivery of triptolide to suppress hepatocellular carcinoma progression through inhibiting de novo lipogenesis."BIOMEDICINE & PHARMACOTHERAPY.2024 Oct;179:117432 60. [IF=14.7] Lai Wang et al."A rationally designed CD19 monoclonal antibody-triptolide conjugate for the treatment of systemic lupus erythematosus."Acta Pharmaceutica Sinica B.2024 Sep;: 59. [IF=4.8] Li Qiang et al."Novel Detoxifier of Spironolactone Against Triptolide-induced Hepatotoxicity through Inhibition of RPB1 Degradation."JOURNAL OF ETHNOPHARMACOLOGY.2024 Aug;:118722 58. [IF=6.5] Zhe Li et al."Homotypic cell membrane-camouflaged biomimetic PLGA nanoparticle loading triptolide for the treatment of hepatocellular carcinoma."DRUG DELIVERY. 57. [IF=6.1] Qiao-Lei Wang et al."Ultrasensitive upconverting nanoprobes for in situ imaging of drug-induced liver injury using miR-122 as the biomarker."TALANTA".2024 Jul;274:126108 56. [IF=2.9] Hanping Liang et al."Triptolide inhibits esophageal squamous cell carcinoma progression by regulating the circNOX4/miR-153-3p/SATB1 signaling pathway."Thoracic Cancer.2024 Jan;: 55. [IF=5.6] Shiyuan Jiang et al."Triptolide attenuates CCL4-induced liver fibrosis by regulating the differentiation of CD4+ T cells in mice."INTERNATIONAL IMMUNOPHARMACOLOGY.2023 Dec;125:111206 54. [IF=5.1] Wang Qian et al."HSP90 Exacerbates Bone Destruction in Rheumatoid Arthritis by Activating TRAF6/NFATc1 Signaling."INFLAMMATION.2023 Oct;:1-13 53. [IF=3.3] Wan Lei et al."A novel pharmaceutical preparation of Tripterygium wilfordii Hook. f. regulates macrophage polarization to alleviate inflammation in rheumatoid arthritis."JOURNAL OF PHARMACY AND PHARMACOLOGY.10.1093/jpp/rgad078 52. [IF=7.9] Zhiyan Qin et al."Mitigation of triptolide-induced testicular Sertoli cell damage by melatonin via regulating the crosstalk between SIRT1 and NRF2."PHYTOMEDICINE.2023 Sep;118:154945 51. [IF=3.222] Chenlei Lv et al."Triptolide protects against podocyte injury in diabetic nephropathy by activating the Nrf2/HO-1 pathway and inhibiting the NLRP3 inflammasome pathway."RENAL FAILURE.2023;45(1):Article: 2165103 50. [IF=9.417] Yunan Zhao et al."Engineering adipocytes for targeting delivery of triptolide derivative and Ce6 for malignant melanoma cytotoxic-PDT synergistic strategy."MATERIALS & DESIGN.2023 Apr;228:111860 49. [IF=2.626] Ma, Rui-jiao et al."Kunxian Capsule Extract Inhibits Angiogenesis in Zebrafish Embryos via PI3K/AKT-MAPK-VEGF Pathway."Chinese Journal of Integrative Medicine.2022 Dec;:1-9 48. [IF=3.685] Guoyao Tan et al."MitoQ alleviates triptolide-induced cardiotoxicity via activation of p62/Nrf2 axis in H9c2 cells."TOXICOLOGY IN VITRO.2023 Feb;86:105487 47. [IF=5.195] Yanqiu Sun et al."Xinfeng capsule inhibits inflammation and oxidative stress in rheumatoid arthritis by up-regulating LINC00638 and activating Nrf2/HO-1 pathway."JOURNAL OF ETHNOPHARMACOLOGY.2023 Jan;301:115839 46. [IF=2.984] Linluo Zhang et al."Protection of catalpol against triptolide-induced hepatotoxicity by inhibiting excessive autophagy via the PERK-ATF4-CHOP pathway."Peerj. 2022 Jan;10:e12759 45. [IF=10.435] Li Zhe et al.Sorafenib and triptolide loaded cancer cell-platelet hybrid membrane-camouflaged liquid crystalline lipid nanoparticles for the treatment of hepatocellular carcinoma.J Nanobiotechnol. 2021 Dec;19(1):1-12 44. [IF=3.411] Zhou Yuyan et al."Arctiin Antagonizes Triptolide-Induced Hepatotoxicity via Activation of Nrf2 Pathway."Biomed Res Int. 2020;2020:2508952 43. [IF=4.617] Li Zhe et al."γ-Cyclodextrin metal–organic framework as a carrier to deliver triptolide for the treatment of hepatocellular carcinoma."Drug Delivery and Translational Research. 2021 Apr 15 42. [IF=5.914] Bo Ma et al."Luteolin Ameliorates Testis Injury and Blood–Testis Barrier Disruption through the Nrf2 Signaling Pathway and by Upregulating Cx43."Mol Nutr Food Res. 2019 May;63(10):1800843 41. [IF=6.419] Yanwen Zheng et al."Membrane protein-chimeric liposome-mediated delivery of triptolide for targeted hepatocellular carcinoma therapy."Drug Deliv. 2021;28(1):2033-2043 40. [IF=6.684] Yi-Sheng Song et al."Validation, Optimization, and Application of the Zebrafish Developmental Toxicity Assay for Pharmaceuticals Under the ICH S5(R3) Guideline."Front Cell Dev Biol. 2021; 9: 721130 39. [IF=9.229] Liangdi Jiang et al."Engineering Exosomes Endowed with Targeted Delivery of Triptolide for Malignant Melanoma Therapy."Acs Appl Mater Inter. 2021;13(36):42411–42428 38. [IF=2.303] Ingrid Elisia et al."Comparison of RAW264.7, human whole blood and PBMC assays to screen for immunomodulators."J Immunol Methods. 2018 Jan;452:26 37. [IF=3.347] Jiamin Kong et al."Triptolide induces mitochondria-mediated apoptosis of Burkitt's lymphoma cell via deacetylation of GSK-3β by increased SIRT3 expression."Toxicol Appl Pharm. 2018 Mar;342:1 36. [IF=3.585] Jie Zhang et al."MitoQ ameliorates testis injury from oxidative attack by repairing mitochondria and promoting the Keap1-Nrf2 pathway."Toxicol Appl Pharm. 2019 May;370:78 35. [IF=5.875] Yongwei Gu et al."Transdermal drug delivery of triptolide-loaded nanostructured lipid carriers: Preparation, pharmacokinetic, and evaluation for rheumatoid arthritis."Int J Pharmaceut. 2019 Jan;554:235 34. [IF=6.4] Li Zhang et al."Fabrication of a triptolide-loaded and poly-γ-glutamic acid-based amphiphilic nanoparticle for the treatment of rheumatoid arthritis."Int J Nanomed. 2018; 13: 2051–2064 33. [IF=10.435] Yang Meng et al."Development of triptolide-nanoemulsion gels for percutaneous administration: physicochemical, transport, pharmacokinetic and pharmacodynamic characteristics."J Nanobiotechnol. 2017 Dec;15(1):1-15 32. [IF=10.435] Gu Yongwei et al."Lipid nanoparticles loading triptolide for transdermal delivery: mechanisms of penetration enhancement and transport properties."J Nanobiotechnol. 2018 Dec;16(1):1-14 31. Elisia, Ingrid, et al. "Comparison of RAW264. 7, human whole blood and PBMC assays to screen for immunomodulators." Journal of immunological methods 452 (2018): 26-31.https://doi.org/10.1016/j.jim.2017.10.004 30. Shan, Qian-Qian, et al. "Cubic and hexagonal liquid crystals as drug carriers for the transdermal delivery of triptolide." Drug delivery 26.1 (2019): 490-498.https://doi.org/10.1080/10717544.2019.1602796 29. Yang, Meng, et al. "Development of triptolide-nanoemulsion gels for percutaneous administration: physicochemical, transport, pharmacokinetic and pharmacodynamic characteristics." Journal of nanobiotechnology 15.1 (2017): 1-15.https://doi.org/10.1186/s12951 28. Zhang, Jie, et al. "MitoQ ameliorates testis injury from oxidative attack by repairing mitochondria and promoting the Keap1-Nrf2 pathway." Toxicology and applied pharmacology 370 (2019): 78-92.https://doi.org/10.1016/j.taap.2019.03.001 27. 汪五清,賀燕妮,曾義斌,張彤,朱瑞政,左付國.雷公藤甲素固體脂質(zhì)納米粒的制備及其抗慢性皮炎濕疹的作用研究[J].上海醫(yī)藥,2021,42(01):14-18+31. 26. 周玉燕,陸蕭雅,夏麗,姚偉強,秦國正,王國棟.牛蒡子苷通過抑制炎癥通路降低雷公藤甲素所致腎毒性[J].南方醫(yī)科大學(xué)學(xué)報,2020,40(10):1399-1405. 25. 曾晶,朱龍.響應(yīng)曲面法優(yōu)化雷公藤甲素的微波萃取工藝[J].生物化工,2020,6(04):1-4. 24. 陳琪,周靜威,孫滿強,李世超,周歡歡,李巖.地黃水提物減輕雷公藤甲素所致肝臟氧化應(yīng)激損傷的實驗研究[J].世界中西醫(yī)結(jié)合雜志,2020,15(12):2241-2245+2251. 23. 周玉燕, 孫玉, 李萍,等. 莫諾苷通過抗氧化應(yīng)激保護雷公藤甲素所致肝細(xì)胞凋亡[J]. 南方醫(yī)科大學(xué)學(xué)報, 2018, 038(008):949-955. 22. 臧勇, 田園, 李衛(wèi)東. 雷公藤甲素通過調(diào)節(jié)TGF-β1信號通路和Hippo信號通路影響腎小管上皮細(xì)胞的上皮-間充質(zhì)轉(zhuǎn)化[J]. 天津醫(yī)科大學(xué)學(xué)報, 2019, 025(003):205-209,224. 21. 方妍妍,萬磊,董文哲,文建庭,劉健.雷公藤甲素通過調(diào)控VEGFA,SDF-1,CXCR4通路改善強直性脊柱炎患者血小板活化的機制[J].中國中藥雜志,2019,44(16):3520-3525. 20. 王愛利, 王蓓蓓, 羅光偉. 雷公藤甲素通過IL-10/Th17細(xì)胞調(diào)節(jié)哮喘小鼠氣道炎癥[J]. 內(nèi)科急危重癥雜志, 2019, 25(4). 19. 萬磊,劉健,黃傳兵,張曉軍,王亞黎,章平衡,孫玥,劉磊.雷公藤甲素調(diào)節(jié)佐劑關(guān)節(jié)炎大鼠滑膜、脾臟、胸腺組織細(xì)胞自噬的實驗研究[J].四川大學(xué)學(xué)報(醫(yī)學(xué)版),2017,48(04):520-525. 18. 羅國平, 孟會寧, 閆夢茹,等. 雷公藤甲素?zé)崦舸假|(zhì)體的制備工藝[J]. 化工科技, 2020, 028(002):46-51. 17. 羅國平, 閆夢茹, 孟會寧,等. 雷公藤甲素普通脂質(zhì)體與包合物脂質(zhì)體體外釋藥特點對比分析[J]. 化工科技, 2020, 028(001):32-36. 16. 李文,楊莉莉,王東明,何翔,丁佩軍,賀旭鋒,邊風(fēng)華,趙曉嫻,陳文君,張慧敏.雷公藤甲素對黑色素瘤A375細(xì)胞EMT通路及侵襲能力的作用研究[J].上海中醫(yī)藥雜志,2020,54(S1):153-155. 15. 李文化, 白雪梅, 吳耀東,等. 雷公藤甲素對早期2型糖尿病大鼠腎臟的保護作用[J]. 河北北方學(xué)院學(xué)報(自然科學(xué)版), 2015, 000(005):77-80. 14. 萬磊, 劉健, 黃傳兵,等. 雷公藤甲素對關(guān)節(jié)炎大鼠心功能的影響及其作用機制探討[J]. 四川大學(xué)學(xué)報(醫(yī)學(xué)版), 2020, v.51(02):82-87. 13. 陳寧南, 萬強. 雷公藤甲素對PM2.5損傷足細(xì)胞的保護作用. 12. 陳凱麗, 易劍峰, 翟文靜,等. 雷公藤甲素在正常大鼠和佐劑性關(guān)節(jié)炎模型大鼠體內(nèi)的藥動學(xué)研究[J]. 中國藥房, 2017, 28(7):923-923. 11. 戴媛媛, 高寒, 劉嫦欽,等. 雷公藤多甙對實驗性結(jié)腸炎大鼠Th17/Treg細(xì)胞分化和平衡的影響[J]. 胃腸病學(xué), 2020, v.25(02):26-31. 10. 范兆峰, 歸小龍, 黃賽杰. 用LC/MS法測定雷公藤甲素納米乳中雷公藤甲素的含量[J]. 藥學(xué)服務(wù)與研究, 2018, v.18(06):50-53. 9. 汪文強, 鄧奇, 肖安菊. 湖北黃石野生馴化扦插雷公藤芽、葉中雷公藤甲素的含量分析[J]. 廣州中醫(yī)藥大學(xué)學(xué)報, 2016, 33(006):868-871. 8. 鄭德杉, 王三亞, 汪文強,等. 樣品處理方法對雷公藤葉中雷公藤甲素含量測定結(jié)果的影響[J]. 湖北理工學(xué)院學(xué)報, 2016, 32(004):58-61. 7. 周玉燕, 王明艷, 潘學(xué)娟,等. 斑蝥酸鈉協(xié)同雷公藤甲素誘導(dǎo)肝癌細(xì)胞株7721凋亡[J]. 中南大學(xué)學(xué)報(醫(yī)學(xué)版), 2016, 41(9):911-917. 6. 黃國東,淮國麗,楊洪吉,王軼,向少偉,覃振林,龐健麗,羅歡,張亞萍,劉振威,許健,呂建珍.復(fù)方仙草顆粒對人腎足細(xì)胞保護作用的研究[J].北京中醫(yī)藥,2017,36(05):410-415+481. 5. 楊盟, 楊帝順, 顧永衛(wèi),等. 基于皮膚,血液雙位點同步微透析技術(shù)的雷公藤甲素納米乳體內(nèi)藥動學(xué)研究[J]. 中國藥學(xué)雜志, 2018, 053(011):894-899. 4. 李芳瓊, 趙東曉, 王娟,等. 基于iTRAQ技術(shù)分析不同濃度的雷公藤甲素作用肺癌細(xì)胞后的差異蛋白表達[J]. 中國新藥雜志, 2018(11). 3. 陳琪, 孫滿強, 李世超,等. 地黃水提物對雷公藤甲素致肝損傷的減毒作用及抗氧化機制[J]. 上海中醫(yī)藥大學(xué)學(xué)報, 2020(4):47-52. 2. 曾晶 朱龍.響應(yīng)曲面法優(yōu)化雷公藤甲素的微波萃取工藝[J].生物化工 2020 6(04):1-4. 1. 趙東曉 陳弘磊 孟冠敏 等. 低濃度雷公藤甲素聯(lián)合順鉑對肝癌細(xì)胞HepG2活性的影響[J]. 浙江中西醫(yī)結(jié)合雜志 2017年27卷5期 366-369頁 2017.